Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Issuance of guidance on management of asymptomatic patients who received epidural or paraspinal injections with contaminated steroid products

Filetype[PDF-801.43 KB]


  • English
    • Details You May Also Like

    Details:

    • Corporate Authors:
      Centers for Disease Control and Prevention (U.S.)
    • Description:
      October 23, 2012, 22:00 ET (10:00 PM ET)

      CDCHAN-00330-2012-23-04-UPD-N

      Issuance of guidance on management of asymptomatic patients who received epidural or paraspinal injections with contaminated steroid products As part of its ongoing investigation of the multistate outbreak of fungal infections, the Centers for Disease Control and Prevention (CDC) continues to assess and revise interim guidance to clinicians involved in the management of patients who received injections with contaminated steroid products distributed by the New England Compounding Center (NECC). Since early in the outbreak, CDC has recommended against antifungal prophylactic or presumptive treatment of exposed asymptomatic patients in the absence of diagnostic testing with results indicating meningitis. This recommendation remains unchanged.

      Nevertheless, CDC recognizes the need to assist clinicians in managing asymptomatic patients who received epidural or paraspinal injections with contaminated steroid products.1 CDC is releasing updated interim guidance to clinicians based on new data that has become available during this investigation.

      CDC analysis suggests that the period of greatest risk for development of fungal meningitis among patients who received epidural or paraspinal injections with contaminated products1 is during the first 6 weeks (42 days) after injection; therefore, additional monitoring of these patients should be considered. Accordingly, CDC provides guidance for asymptomatic patients who received epidural or paraspinal injections with contaminated steroid product within the last 6 weeks (42 days), and those who received such products longer than 6 weeks (42 days) ago. For specific details about the updated guidance, see Guidance on Management of Asymptomatic Patients Who Received Epidural or Paraspinal Injections with Contaminated Steroid Products (http://www.cdc.gov/hai/outbreaks/clinicians/

    • Subjects:
    • Series:
      HAN ; 330
    • Document Type:
      HAN Health Advisory
    • Place as Subject:
      United States
    • Location:
      North America
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov